Evidence map›Paper›PMID 41011595›Full record

ReviewMolecules (Basel, Switzerland)2025

Advancing Brain Health Naturally: β-Caryophyllene and Xanthohumol as Neuroprotective Agents.

Stanislava Ivanova, Zoya Dzhakova, Velislava Todorova, Radka Boyuklieva, Plamen Simeonov, Plamen Katsarov

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stanislava IvanovaDepartment of Pharmacognosy and Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.ORCID 0000-0003-1282-7868
Zoya DzhakovaDepartment of Pharmacognosy and Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
Velislava TodorovaDepartment of Pharmacognosy and Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.ORCID 0000-0001-9840-6890
Radka BoyuklievaResearch Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.ORCID 0000-0001-8594-1712
Plamen SimeonovResearch Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.ORCID 0009-0009-2333-9879
Plamen KatsarovResearch Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.ORCID 0000-0002-9158-6208

Funding

This research was funded by the European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria, project No. BG-RRP-2.004-0007-C01. BG-RRP-2.004-0007-C01
6 · The paper itself

Abstract

Neurodegenerative diseases (NDDs) represent a class of incurable and progressive disorders characterized by the gradual degeneration of the structure and function of the nervous system, particularly the brain and spinal cord. A range of innovative therapeutic approaches is currently under investigation, such as stem cell-based therapies, gene-editing platforms such as CRISPR, and immunotherapies directed at pathogenic proteins. Moreover, phytochemicals such as β-caryophyllene and xanthohumol have demonstrated significant neuroprotective potential in preclinical models. These natural agents exert multifaceted effects by modulating neuroinflammatory pathways, oxidative stress responses, and aberrant protein aggregation-pathological mechanisms that are central to the development and progression of neurodegenerative disorders. Recent investigations have increasingly emphasized the optimization of the pharmacokinetic properties of β-caryophyllene and xanthohumol through the development of advanced drug-delivery systems, including polymer- and lipid-based nano- and microscale carriers. Such advancements not only enhance the bioavailability and therapeutic potential of these phytochemicals but also underscore their growing relevance as natural candidates in the development of future interventions for neurodegenerative disorders.

Indexed as

BrainFlavonoidsNeurodegenerative DiseasesNeuroprotective AgentsPolycyclic SesquiterpenesPropiophenonesAnimalsDrug Delivery SystemsHumanscaryophylleneFlavonoidsNeuroprotective AgentsPolycyclic SesquiterpenesPropiophenonesxanthohumolnanotechnologynatural medicineneurodegenerative diseasesneuroprotectionxanthohumolβ-caryophyllene

Identifiers

PMID41011595
PMCPMC12472692

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.